首页 | 本学科首页   官方微博 | 高级检索  
   检索      


Role of endogenous regucalcin in protein tyrosine phosphatase regulation in the cloned rat hepatoma cells (H4-II-E)
Authors:Inagaki  Shyuichiroh  Misawa  Hiroyuki  Yamaguchi  Masayoshi
Institution:(1) Department of Oncology, The Jikei University School of Medicine, Nishi-Shinbashi, Minato-ku, Tokyo, 105-8461, Japan;(2) Department of Oncology, Department of Internal Medicine (1) of Daisan Hospital, Japan;(3) Deparment of Internal Medicine (1) of Daisan Hospital, Japan;(4) Department of Molecular Genetics, Department of Internal Medicine, The Jikei University School of Medicine, Nishi-Shinbashi, Minato-ku, Tokyo, 105-8461, Japan
Abstract:Etoposide is a potent anticancer agent that is used to treat various tumors. We have investigated the dose-dependent effect of etoposide on apoptosis using chronic myeloid leukemia K562 cells treated with low (5 mgrM) or high (100 mgrM) concentrations of the drug. At a low concentration, etoposide induced little apoptosis at 24 h, while about 20% of the cells showed apoptosis morphologically at a high concentration. Processing of caspase-3 was slightly detected from 12 h and became obvious at 24 h with 100 mgrM etoposide. Caspase-3-like protease activity was detected at 24 h with a high concentration. Moreover, these changes were accompanied by cleavage of poly ADP ribose polymerase (PARP). Changes of the mRNA levels of most apoptosis-regulating genes were not prominent at both concentrations, except for the rapid induction of c-IAP-2/HIAP-1 and the down-regulation of Bcl-XL by 100 mgrM etoposide. The downregulation of Bcl-XL protein occurred from 6 h, while Bax protein conversely showed a slight increase from 6 h. Taken together, the present findings show that the dose-dependent apoptotic effect of etoposide is based on a change in the balance between Bcl-XL and Bax, which precedes the activation of caspase-3.
Keywords:etoposide  Bcl-XL  Bax  apoptosis  K562 cells
本文献已被 PubMed SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号